A5026586699- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Histone Deacetylase Inhibitors Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Renal Transplantation Outcomes and Treatments
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Retinoids in leukemia and cellular processes
- Immune Cell Function and Interaction
- Inhalation and Respiratory Drug Delivery
- Transplantation: Methods and Outcomes
- Childhood Cancer Survivors' Quality of Life
- Air Quality and Health Impacts
- Nail Diseases and Treatments
- Liver Disease Diagnosis and Treatment
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- T-cell and Retrovirus Studies
- CAR-T cell therapy research
Johns Hopkins University
2009-2025
Johns Hopkins Medicine
2016-2025
Sidney Kimmel Comprehensive Cancer Center
2019-2024
Johns Hopkins Hospital
2016-2023
Sidney Kimmel Cancer Center
2023
U-M Rogel Cancer Center
2022
Comprehensive Blood & Cancer Center
2022
National Heart Lung and Blood Institute
2022
Emory University
2012-2014
Winship Cancer Institute
2012
Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing hundreds of genes, but ensuing biologic and therapeutic consequences this missplicing are not well understood. Here we have provided evidence by mutant altered transcriptome, proteome, metabolome human cells, leading to missplicing-associated downregulation metabolic decreased mitochondrial respiration, suppression serine synthesis pathway. We also found induces...
Aberrant FLT3 receptor signaling is common in acute myeloid leukemia (AML) and has important implications for the biology clinical management of disease. Patients with FLT3-mutated AML frequently present critical illness, are more likely to relapse after treatment, have worse outcomes than their wild type counterparts. The been transformed by development inhibitors, which now use frontline relapsed/refractory settings. However, many questions regarding optimal approach treatment these...
Abstract Blood or marrow transplantation (BMT) outcomes using haploidentical donors (Haplo) and posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis compare favorably to HLA-matched calcineurin inhibitor–based prophylaxis. A recent Center for International Marrow Transplant Research analysis of patients receiving homogenous PTCy-based found that, with reduced intensity conditioning, Haplo BMTs had worse than matched unrelated donor (MUD) BMTs. Due...
Patients with myeloid neoplasms loss-of-function TP53 mutations and erythroid differentiation have poor outcomes, a better understanding of disease biology is required. Upregulation interferon-γ (IFN-γ) signaling has been associated acute leukemia (AML) progression chemotherapy resistance, but its drivers remain unclear. In this study, we found that the surface receptor C-C motif chemokine receptor-like 2 (CCRL2) overexpressed in AML compared to other subtypes healthy hematopoietic cells....
Abstract Chronic infection with the hepatitis B virus (HBV) is most important risk factor for hepatocellular carcinoma (HCC). However, determinants of HCC in infected individuals are not well understood. We prospectively evaluated association between acquired HBV 1762T/1764A double mutations and among 49 incident cases 97 controls seropositive surface antigen at baseline from a cohort 18,244 men Shanghai, China, enrolled during 1986 to 1989. Compared carriers without mutations, chronic...
We describe outcomes after post-transplantation cyclophosphamide and nonmyeloablative conditioning-based allogeneic blood or marrow transplantation for myelofibrosis using matched mismatched related unrelated donors. The conditioning regimen consisted of fludarabine, cyclophosphamide, total body irradiation. Forty-two patients were included, with a median age 63 years, whom 19% had Dynamic International Prognostic Scoring System (DIPSS)-plus intermediate-1 risk, 60% intermediate-2 21%...
Mantle cell lymphoma (MCL) is a rare B that varies in clinical behavior with some patients experiencing aggressive disease short survival, whereas others have indolent behavior. We examined the association between primary site and survival MCL to identify subgroups distinct characteristics.We analyzed United States Surveillance, Epidemiology End Results Program database for cases reported from 2000 through 2009. Kaplan-Meier curves Cox proportional hazard models were used estimate effect of...
Follicular lymphoma (FL) is an indolent malignancy of germinal center B cells with varied incidence across racial groups and geographic regions. Improvements in the classification non-Hodgkin subtypes provide opportunity to explore associations between environmental exposures FL incidence. Our paper found that aspects Western lifestyle including sedentary lifestyle, obesity, diets high meat milk are associated increased risk FL. Diets rich fruits vegetables, polyunsaturated fatty acids,...
"Small Devices, Big Problems: Addressing the Global Warming Potential of Metered-Dose Inhalers." Annals American Thoracic Society, 19(7), pp. 1090–1092
BACKGROUND An increased risk of non‐Hodgkin lymphoma (NHL) has been observed among individuals with occupational exposure to benzene, but the those living near benzene release sites not well described. METHODS To investigate spatial patterns NHL incidence and association between distance sites, authors linked geocoded data on in Georgia from 1988 1998 using Environmental Protection Agency's (EPA) Toxics Release Inventory (TRI), census tract level population statistics, Comprehensive Cancer...
There are currently no known predictors of myelodysplastic syndrome (MDS)/myeloproliferative overlap neoplasm (MPN) patients' response to hypomethylating agents (HMA). Forty-three patients with MDS/MPN who were treated HMA during chronic phase and had next-generation sequencing using the established 63-genes panel identified. Complete partial remission marrow assessed based on International Working Group criteria. On univariate analysis, younger age, higher number mutations, mutations in...
The combination of venetoclax and hypomethylating agent (HMA/venetoclax) has emerged as a treatment option for patients with de novo acute myeloid leukemia (AML) who are unfit to receive intensive chemotherapy. In this single-center retrospective study, we evaluated clinical outcomes following HMA/venetoclax in 35 advanced myeloproliferative neoplasms, myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes or AML extramedullary disease. composite complete remission (CR) rate...
High-dose post-transplantation cyclophosphamide (PTCy) is an effective platform for prevention of severe graft-versus-host disease (GVHD) after allogeneic bone marrow (BM) transplantation with mismatched unrelated donors (mMUDs). Previous studies evaluating PTCy mMUDs favored BM allografts over peripheral blood stem cell (PBSCT) due to concerns that PBSCT may be associated increased risk acute and chronic GVHD. In addition, haploidentical high rates cytokine release syndrome (CRS), which...
Mantle cell lymphoma (MCL) remains incurable with conventional chemotherapy without consensus on the optimal initial treatment. We examined our single center experience frontline therapy for patients MCL in consecutive cases diagnosed 1995-2011. Among 81 patients, median age was 59 (28% were ≥65 years of age), 95% had stage III/IV disease and 54% a low risk International Prognostic Index score. Thirty-five percent (n=28) received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...